Clinical effect of tongxinluo capsule in the treatment of chronic pulmonary heart disease

doi:10.3877/cma.j.issn.2095-6568.2018.02.003

Abstract

Abstract:

Objective

To observe the clinical effect of tongxinluo capsule in the treatment of chronic pulmonary heart disease.

Methods

A total of 75 CPHD patients admitted to Henan Provincial People's Hospital from August of 2016 to December of 2017 were randomly divided into the control group (37 cases) and the study group (38 cases). The control group received routine treatment, and the study group received tongxinluo capsule as an assistant treatment on the basis of routine treatment. Total therapeutic efficiency of the two groups was calculated, and LVEF, CO and ET-1, NO levels were compared before and after treatment.

Results

The total effective rate of the study group (94.73%) was higher than that of the control group (78.38%), and the difference was statistically significant (P<0.05). The levels of LVEF and CO in the study group were lower than those in the control group (P<0.05). The level of ET-1 in the study group was lower than that in the control group, and the level of NO in the study group was higher than that in the control group (P<0.05).

Conclusion

Tongxinluo capsule has a good clinical effect in the adjuvant treatment of CPHD. It can effectively improve the cardiac function and vascular endothelial function of patients, and can be widely used in clinical practice.

Key words: Chronic pulmonary heart disease, Tongxinluo capsule, Cardiac function, Vascular endothelial function

Erhu Tian, Jiangtao Cheng. Clinical effect of tongxinluo capsule in the treatment of chronic pulmonary heart disease[J]. Chinese Journal of Heart and Heart Rhythm(Electronic Edition), 2018, 06(02): 71-73.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxzyxldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-6568.2018.02.003

https://zhxzyxldzzz.cma-cmc.com.cn/EN/Y2018/V06/I02/71

Figures/Tables 3

References 6

[1]	孙印，徐亚杰，韦海燕，等. 探讨BNP、TNI、D－Dimer及心脏彩超在老年慢性肺源性心脏病患者病情评估中的临床价值[J]. 临床肺科杂志，2018, 23(9): 1645-1648.
[2]	解鑫隆，徐朝军，项宇，等. 通心络胶囊对冠状动脉旁路移植术后桥血管通畅情况的影响[J]. 现代中西医结合杂志，2018, 27(25): 2737-2741.
[3]	王亚玲. 通心络胶囊联合参麦注射液治疗慢性肺源性心脏病急性加重期疗效观察[J]. 新中医，2015, 47(4): 37-39.
[4]	孙智睿，郎琢琳. 通心络胶囊对冠心病冠状动脉支架植入术后患者NF－κB、IL－6、TNF－α表达的影响及治疗效果分析[J]. 中国医学前沿杂志(电子版), 2018, 10(8): 43-45.
[5]	向寿培. 通心络胶囊联合美托洛尔和卡托普利对慢性肺源性心脏病患者血清炎性细胞因子和血管内皮功能的影响[J]. 健康之路，2017, 16(4): 50-51.
[6]	蒋魏，邹红. 对老年脑梗死患者使用通心络胶囊进行治疗对其IMT、血液粘稠度、D－二聚体、及Hcy水平的影响[J]. 当代医药论丛，2018, 16(15): 110-113.

组别	例数	显效	有效	无效	总有效率
对照组	37	10	19	8	78.38
研究组	38	16	20	2	94.73
χ²值	?	?	?	?	4.341
P值	?	?	?	?	0.037

组别	例数	显效	有效	无效	总有效率
对照组	37	10	19	8	78.38
研究组	38	16	20	2	94.73
χ²值	?	?	?	?	4.341
P值	?	?	?	?	0.037

组别	例数	LVEF(%)		t值	P值	CO(L/min)		t值	P值
组别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
对照组	37	32.96±4.43	42.27±3.94	9.552	0.000	4.11±0.31	4.60±0.66	4.088	0.000
研究组	38	32.81±3.98	48.91±3.58	18.540	0.000	4.08±0.37	5.11±0.59	9.117	0.000
t值	?	0.154	7.642	?	?	0.380	3.530	?	?
P值	?	0.878	0.000	?	?	0.705	0.001	?	?

组别	例数	LVEF(%)		t值	P值	CO(L/min)		t值	P值
组别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
对照组	37	32.96±4.43	42.27±3.94	9.552	0.000	4.11±0.31	4.60±0.66	4.088	0.000
研究组	38	32.81±3.98	48.91±3.58	18.540	0.000	4.08±0.37	5.11±0.59	9.117	0.000
t值	?	0.154	7.642	?	?	0.380	3.530	?	?
P值	?	0.878	0.000	?	?	0.705	0.001	?	?

组别	例数	ET－1(ng/ml)		t值	P值	NO(mg/L)		t值	P值
组别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
对照组	37	90.63±8.17	69.93±7.59	11.291	0.000	30.36±5.35	43.92±5.63	10.620	0.000
研究组	38	90.81±8.42	57.51±8.32	17.342	0.000	30.51±5.17	55.76±5.82	19.995	0.000
t值	?	0.094	6.749	?	?	0.123	8.951	?	?
P值	?	0.925	0.000	?	?	0.902	0.000	?	?

Please choose a citation manager

Content to export